中慧元通 is a biotechnology company engaged in vaccine research and development, regulatory filing, industrialization and commercial sales. The company has obtained clinical approvals for four Class I new‑drug candidates: pediatric and adult quadrivalent influenza virus subunit vaccines, a recombinant varicella‑zoster (shingles) vaccine, and a 9‑valent recombinant human papillomavirus (HPV) vaccine; it also holds a Class‑IX clinical approval for a 23‑valent pneumococcal polysaccharide vaccine. Its quadrivalent influenza subunit vaccine is developed with the company’s patented technology, which the article describes as delivering high purity and good safety and being especially suitable for children and the elderly. The article cites WHO’s 2018–2019 northern‑hemisphere recommended quadrivalent vaccine components in describing the product. Company activities explicitly cover R&D, registration submissions, industrialization and sales. The report also notes the company completed a Pre‑IPO financing round of more than CNY 600 million.

Total raised

$93M

Funding rounds

1

Latest round

Equity

Latest activity

Aug 2021